For nearly a decade, our center performed thromboelastograms (TEGs) to analyze coagulation profiles, allowing rapid data-driven blood component therapy. After consensus recommendations for massive transfusion protocols (MTPs), we implemented an MTP in October 2009 with 1:1:1 ratio of blood (red blood cells [RBC]), plasma (fresh-frozen plasma [FFP]), and platelets. We hypothesized that TEG-directed resuscitation is equivalent to MTP resuscitation.
T rauma is the leading cause of morbidity and mortality for patients younger than 44 years, 1 with uncontrolled hemorrhage and exsanguination resulting in 30% to 40% of fatalities in these patients. 2 Blood loss from trauma often results in a triad of coagulopathy, hypothermia, and acidosis, which further complicates resuscitation and operative control of bleeding.
In response to this lethal triad, current resuscitation strategies use ''Damage Control Resuscitation.'' This method uses a systematic approach to major trauma with early transfusion of blood (red blood cells [RBC] ), plasma (fresh-frozen plasma [FFP] ), and platelets in a 1:1:1 ratio, 3 combined with damage control surgery, in an effort to simultaneously control surgical and nonsurgical bleeding. Severely injured trauma patients may require massive transfusions, often defined as requiring greater than 10 units (U) of packed RBCs in a 24-hour period. 4 In the 1970s, mortality was as high as 90% in patients requiring massive transfusion. 5 However, with improved transfusion practices and surgical approaches, mortality rates have declined to 30% to 70%. 6 Specifically, the addition of FFP improved mortality rates after hemorrhagic trauma primarily because of correction of coagulopathy. 7 Although there is universal agreement regarding the use of FFP, debate continues on optimal transfusion strategies. With concerns for increased incidence of multiple organ failure and adult respiratory distress syndrome with increased use of blood products, 8 optimum ratios are still being harangued in the literature and range from FFP:RBC in a ratio of 1:1 to 1:3.
9Y11
Additional mortality benefit has been reported with respect to increasing the ratio of platelets to RBC via a retrospective review of trauma patients with large volume blood losses. 12 An alternate resuscitation strategy involves the use of a thromboelastogram (TEG) to analyze coagulation profiles and guides resuscitation via a rapid data-driven blood component therapy. Developed in 1948, the TEG graphically represents clotting activity from initiation of the clotting cascade to fibrinolysis, reflecting the entire hemostatic process. 13 Although more prominently used in surgical arenas other than trauma, 14Y17 studies have shown that TEG 18Y21 may more accurately reflect postinjury coagulopathy than other classic measures of coagulopathy, such as prothrombin time, partial thromboplastin time, and international normalized ratio.
For nearly a decade, our center performed TEG-directed resuscitation. After multiple recommendations from trauma literature advocating adoption of massive transfusion protocols (MTPs) with transfusion of a 1:1:1 ratio of RBC, FFP, and platelets, we implemented MTP in October 2009. The purpose of this study was to examine our experience with MTP implementation as compared with our previous practice of TEGdirected resuscitation. We hypothesized that TEG-directed resuscitation is equivalent to MTP resuscitation.
PATIENTS AND METHODS
This study took place at Ben Taub General Hospital, a Level I trauma center in the Harris Health System in Houston, Texas. MTP was implemented at the trauma center in October 2009 with the goal of improving transfusion practices. Our MTP is as follows: on activation, 6U of type-specific RBC, 2U of jumbo FFP (1 jumbo FFP = 2U FFP), and 1 platelet apheresis (also known as a ''six-pack'') is prepared on receipt of a blood sample for type and crossmatch. For each subsequent request for blood products, a cooler holding 6U RBC, 2U jumbo FFP, and 1 platelet apheresis is brought to the patient until the MTP is terminated. Once a patient arrives to the emergency department with a life-threatening injury, activation of MTP is at the discretion of the attending surgeon or anesthesiologist. Because of the rapid nature of trauma assessment, activation is decided based on clinical judgment and consists of an immediate call to the blood bank verbally requesting MTP. Once activated, MTP proceeds as previously described until deactivated. The end points for resuscitation are not explicitly defined by the protocol and are determined by a variety of patient factors, including laboratory and clinical data.
We queried our trauma database for patients who received 6U or more RBC and 10U or more RBC in the first 24 hours of admission from January 2008 through June 2010, a time frame 21 months before and 21 months after MTP implementation. We retrospectively analyzed the database after defining two cohort groups: (1) patients before protocol implementation (preMTP patients) and (2) patients after protocol implementation (MTP patients). We included any trauma patient with direct admittance from the emergency department requiring 6U or more and 10U or more RBC in the first 24 hours. Although the most commonly used definition of massive transfusion is a requirement of 10U or more RBC, there is evidence that suggests that lesser transfusions of RBC may have improved outcomes if transfused in a 1:1 (RBC:FFP) ratio; 22 thus, we broadened our criteria to include patients with 6U RBC. Exclusion criteria included patients with traumatic brain injury and younger than 15 years. Data obtained included patient demographics; mechanism of injury (MOI); Injury Severity Score (ISS); volume of RBC, FFP, platelets, and crystalloid in the first 24 hours; intensive care unit (ICU) days; mechanical ventilation days; and early (G24 hours), delayed (924 hours), and 30-day mortality.
Before implementation of MTP, we used TEG data to guide resuscitation. FFP or platelets were given in conjunction with blood based on the TEG results (alterations in R, angle, or MA) obtained in the operating room or ICU. Both the procurement and interpretation of the TEG have been well described previously. 23 See Figure 1 for example TEG and replacement algorithm.
Continuous variables were examined using Student's t-test or Mann-Whitney U test for nonparametric data, and categorical variables were analyzed using Pearson's W 2 analysis. Primary outcome was 30-day mortality, whereas secondary outcomes included early (G24 hours) and delayed (924 hours) deaths; total volume and individual volumes of RBC, FFP, and platelets in the first 24 hours of admission; volume of crystalloid in the first 24 hours of admission; and number of ICU days and mechanical ventilation days. All analyses were performed using SPSS software (IBM SPSS Statistics 19, release 19.0.0, Somers, NY).
RESULTS
Patient demographics such as age and sex were similar between the two groups, with a mean age of 35 years and predominantly male sex. For patients with 6U or more RBC, preMTP patients had a significantly greater percentage of penetrating trauma than MTP patients (62 vs. 38%, p = 0.02), whereas patients with 10U or more RBC did not have a significantly different MOI. ISS was similar among all compared groups ( Table 1) . As shown in Table 2 , there was no significant difference in total blood products (RBC, FFP, platelets) in patients with 6U or more RBC or 10U or more RBC. Patients who received 6U or more RBC had no significant difference in FFP or platelet volume after MTP implementation. Patients who received 10U or more RBC, however, had increased FFP in patients with blunt MOI (p = 0.02), but patients with penetrating MOI did not have a significant increase in FFP. No patients with 10U or more RBC had a significant difference in platelets. For all patient groups and all MOIs, there was a significant decrease in crystalloid volume transfused after MTP implementation (p G 0.001 to p = 0.01). With respect to the ratios of RBC:FFP and RBC:platelets, blunt MOI patients with 6U or more RBC had significant improvement in the ratio of RBC:FFP (3.4:1 preMTP vs. 2.1:1 MTP, p = 0.02). All other patient groups had no significant differences in transfusion ratios after MTP implementation. For all patients, there was no significant difference in number of days on a ventilator or of ICU days after implementation of MTP ( Table 3) .
As demonstrated in Table 4 , in patients receiving 6U or more RBC, there was no significant difference in 30-day mortality after MTP implementation. There was also no significant difference in 30-day mortality for patients with 10U or more RBC with blunt MOI. However, in patients with penetrating MOI, mortality was higher after MTP implementation if they received 10U or more RBC (33 vs. 54%, p = 0.04).
Patients who received 10U or more RBC with blunt MOI had more late deaths (p = 0.04), whereas penetrating MOI patients had more early deaths (p = 0.01). Mortality was further stratified based on hours from admission (0Y2, 2Y6, and 6Y24 hours), with results available in Table 5 . In addition, there were no significant differences in nonsurvivable injury between the two patient groups. Multiple regression analysis indicated that age (p = 0.03), ISS (p G 0.001), and RBC volume (p = 0.001) are the only independent predictors of mortality for this patient group (Table 5) .
DISCUSSION
The concept of 1:1:1 transfusion ratios of blood products dates back to early combat situations when whole blood was used for resuscitation in World War I and World War II. 24 In current conflicts, whole blood is still used; however, it is not generally available to civilians. In the civilian population, component therapy was thought to be better for resource utilization and reduction of infection risk associated with transfusion; 25 thus, blood components were replaced based on deficiencies shown in laboratory testing. This seemed to be a proper and prudent method for medical patients; but in trauma patients, surgeons recognized component therapy had yet to be perfected. To more closely mimic whole blood while conserving blood component resources, varying transfusion ratios of RBC:FFP:platelets have been attempted via MTP, with proponents stating that ratios from 1:1:1 (RBC:FFP:platelets) to 1:3 (FFP:RBC) have shown decreased mortality in civilian trauma. 10,11,26Y29 Regardless of the ratio of blood products, the process of component separation from whole blood degrades essential factors that cannot be replaced. For example, a unit of FFP contains only 80% of the amount of coagulation factors found in a unit of whole blood. 30 MTP activation also replaces coagulation factors and platelets earlier in the resuscitation process, which attempts to address the acute coagulopathy of trauma. 31Y33 In fact, by adopting a systematic way to provide blood products at the point of care, MTP implementation in limited-experience trauma centers can result in improvements in mortality. Use of TEGs during trauma resuscitation offers a window into the coagulation process, with real-time interactive data that are quickly available and more comprehensive than those of classic coagulation measurements. 21 Prothrombin time, partial thromboplastin time, and international normalized ratio are inherently insufficient in their use during trauma because they can take upward of an hour to determine, and only reflect, the initiation of the clotting process. 34 TEG data appear, in trauma literature, as a fast and accurate test for determining coagulopathy, 35 as a predictor of need for blood transfusion, 20 and as a potential tool for goal-directed resuscitation. 36 As an institution that previously used TEG to replace blood products on an as-needed basis, but converted to MTP as a driving force in our trauma resuscitation, we felt compelled to compare data before and after MTP initiation.
Our patient demographics were quite similar in both cohorts; however, there was significantly more penetrating trauma in the preMTP patients who received 6U or more RBC. Multiple regression analysis did not determine that MOI was a significant predictor of mortality, whereas ISS, which was a significant predictor of mortality, was similar between the two groups. Age was also similar between the two groups, with a mean of 32 to 36 years of age, but determined to be an independent predictor of mortality. This is not unexpected because older patients have less physiologic reserve to survive a severe trauma.
Because the primary aim of an MTP is to address coagulopathy by increasing the use of FFP and platelets, we would presume that there would be a decrease in volume of RBC transfused because of less patient bleeding, as seen in the study by Zink et al. 37 However, in our patient population, the volume of RBC transfused did not significantly change after MTP initiation. FFP volume increased significantly in blunt MOI patients receiving 10U or more RBC but not in penetrating MOI patients receiving 10U or more RBC or any group receiving 6U or more RBC. One would expect that FFP volumes would increase significantly across all stratifications within this group. Furthermore, the blunt MOI patients receiving 10U or more RBC had equivalent mortality before MTP activation, using significantly lower volumes of FFP. This brings to question whether MTP causes unnecessary transfusion of FFP in patient groups who may not require it. Because of the inherent risks that accompany massive transfusion of blood products such as transfusion reactions and exposure to infectious agents, TEG-directed resuscitation may have an edge on MTP with respect to decreasing blood product utilization and infectious exposure, with equivalent outcomes.
Interestingly, ratios of RBC:FFP and RBC:platelets were also similar before and after implementation of MTP, with the exception of blunt MOI patients with 6U or more RBC who received statistically lower ratios of RBC:FFP (p = 0.02). This group who received improved transfusion ratios had no improvement in mortality, however, and these results lead us to believe that TEG resuscitation already provided appropriate ratios of blood products but based on laboratory data rather than preprescribed ratios. Platelet volumes did not increase in any group after MTP implementation, and patients who did receive platelets received them in a ratio relatively similar in preMTP and MTP groups. The significant decrease in crystalloid volume across all groups was likely caused by earlier blood product resuscitation with MTP implementation, negating the need for crystalloid boluses.
Examining 30-day mortality, there was a significant increase in mortality from 33% to 54% after MTP initiation in penetrating MOI patients who required 10U or more RBC, and these patients also had increased early deaths. Interestingly, this is the same group that did not have a significant increase in FFP volume after MTP initiation as compared with blunt trauma patients who received 10U or more RBC. We already know that coagulopathy exists from trauma alone 31Y33 before we have the chance to further exacerbate the process with resuscitation methods, particularly if the injury is severe. Furthermore, a 1:1:1 strategy falls short of approximating whole blood hematocrit, platelet count, and coagulation factor activity. 30 It is entirely possible that, with activation of MTP, we transfused FFP less aggressively in individual patients who may have required more because of coagulopathy as compared with our TEG-directed approach (which would have shown increased need in real-time fashion), thus worsening our mortality. The Denver Report from Kashuk and colleagues 11 was the first to question 1:1:1 ratios, showing that 1:2 and 1:3 ratios had improved predictive probability of mortality as compared with 1:1. Another compelling study from Davenport and colleagues 38 also went further to show that the beneficial effects of increasing the ratio of FFP:RBC was only seen in patients who were coagulopathic, and that no additional benefit was seen in coagulopathic patients receiving ratios of 1:1 as compared with those receiving 1:2 or 3:4. These studies seem to indicate that early rTEG/TEG/ROTEM data showing the ''bad actors'' can help us determine who truly requires aggressive management, and that 1:1:1 empiric transfusion may be potentially wasteful because it did not benefit their patient population more as compared with those who received lower ratios.
An additional factor to consider is that patient and injury variability preclude a ''one-size-fits-all'' approach. Clearly, there are a variety of differences in the patient response to injury. In fact, there is a differing degree of tissue factor activation between blunt and penetrating trauma in the same injured patient. The ability of the patient to sustain injury and maintain homeostasis is dependent on comorbidities as well as the anatomy and physiology of the patient at the time of injury in addition to genomic and proteomic factors that we are only beginning to elucidate. We feel that TEG is a very capable measure of the current and evolving status of the coagulation cascade of the injured patient and is able to help properly identify when a patient lacks adaptive mechanisms and requires more aggressive intervention for hemostasis. Furthermore, it is rapidly available at the point of care, allowing the clinician to tailor resuscitation to the real-time physiology of the patient.
All of the previous assertions showing decreased blood product utilization and improved mortality are based on past studies comparing non-MTP resuscitation with MTP resuscitation or retrospectively comparing outcomes in patients who happen to receive higher ratios. Our study is a novel approach, comparing TEG-directed resuscitation with MTP resuscitation, which, to our knowledge, has not been previously published. Of course, our study has limitations. A randomized controlled trial comparing TEG-directed resuscitation with MTP resuscitation would be the preferred method of study, and as a retrospective review, our study has its own inherent weaknesses. Catch-up bias limits this study because it looks at total blood products in 24 hours. Patients can appear to receive an appropriate ratio over extended periods that may be completely different if evaluating within the first 6 hours of admission, 37 which would better reflect true clinical practice;
28,39 but unfortunately, our trauma database did not time stamp blood products before the 24-hour mark, and this will be important data to capture in future prospective studies. Survival bias is also in play in this study because some patients die quickly in the operating room before they receive their first unit of FFP or platelets but could potentially receive a large amount of blood with rapid transfusion devices. Time to transfusion is also not evaluated in our study, and we suspect that time to first unit of FFP will have an important role in improving the coagulopathy of these trauma patients. 40 We also did not capture any data to allow us to establish increased risk of exposure to infectious agents or a cost analysis of using more FFP in blunt MOI patients with 10U or more RBC who had equivalent mortality outcomes, but this should certainly be investigated in future studies. This study also does not address other potential products such as cryoprecipitate, factor rVIIa, or other coagulation concentrates. Cryoprecipitate was added to our MTP after the dates inclusive of this study and was rarely used in either time period, thus we did not examine its effect. In addition, although giving an antifibrinolytic of choice is mentioned in our algorithm in Figure 1 , this has also only recently been added to our resuscitation protocol and was not given to patients in this study but could certainly be examined at a future date.
CONCLUSION
It is well known that severely injured trauma patients arrive coagulopathic to the hospital. Aggressive resuscitation with empiric implementation of a 1:1:1 replacement of blood products is currently advocated. However, even with this aggressive strategy of transfusion, only 65% of coagulation factor activity is delivered to the patient in extremis. This approach may not be adequate for all patients. Based on our clinical outcomes, we note that, in our patient population, TEG-directed resuscitation is superior to MTP in massively transfused penetrating MOI patients receiving 10U or more RBC. TEG-directed resuscitation is equivalent to standardized MTP for all patients receiving 6U or more RBC and is also equivalent to standardized MTP for blunt MOI patients receiving 10U or more RBC. MTP worsened mortality in penetrating MOI patients receiving 10U or more RBC, indicating a continued need for TEG-directed therapy.
A 1:1:1 strategy may not be adequate in all patients. MTP has shown in multiple studies to benefit mortality through balanced ratios of blood products and more timely initiation of transfusion. MTP has certainly helped establish transfusion protocols in trauma centers with less experience in massive transfusion. Debate will be ongoing as to optimal ratios to optimize mortality and minimize waste. In our investigation, TEG-directed therapy seems to provide optimal ratios through laboratory data rather than a preprescribed transfusion practice. Thus, utilization of TEG in conjunction with MTP may help elucidate those patients who require more aggressive resuscitation because of their unique physiologic response to injury and, inversely, allow us to avoid unnecessary transfusion of products when they are not needed. Clearly, there are some patients with profound susceptibility to derangement of their coagulation profile. Likewise, there are patients who have a unique ability to withstand severe injury. The underlying etiologies of this predisposition to be resilient or susceptible to injury remain to be elucidated. We propose that TEG serves as an index marker of this ability to mount a homeostatic response to injury. After review of these data, our current approach emphasizes TEG utilization in an effort to guide correction of coagulopathy at the point of care, with MTP used as a systembased infrastructure solution to provide logistic transport of blood products to the bedside. Further studies, particularly randomized controlled trials, are recommended to investigate 
DISCUSSION
Dr. Ernest E. Moore (Denver, Colorado): Knowing the academic congeniality in Houston, I'm surprised the authors did not entitle this report ''TEG Guided Resuscitation is Superior to 1:1:1.'' In fact, as most would anticipate, goal-directed therapy should be superior to fixed product administration considering the dynamic status of the acute coagulopathy of trauma. In sum, the data are compelling. But, as usual, the retrospective cohort study design raises a number of questions.
First, you indicated that the massive transfusion protocol was activated by clinical judgment. What was the sensitivity and specificity of this policy? And did this change over the study period?
In other words, was the MTP activated unnecessarily leading to excessive blood component use? Or, conversely, activated late, resulting in an advanced coagulopathy?
Second, it is important to recognize that standard TEG, that is intrinsic activated, was employed rather than the more current rapid TEG that is stimulated by both intrinsic and extrinsic agonist.
Irrespective of the activators, TEG provides readouts that suggest the need for clotting factors, platelets, fibrinogen, and anti-fibrinolytics. What threshold values did you employ for these individual components? And in what order did you prioritize their administration?
More specifically, how often was cryoprecipitate used? And how often were anti-fibrinolytic agents given in these two groups? One of the undisputable advantages of TEG is the prompt diagnosis and monitoring of fibrinolysis.
Third, as with most retrospective hemostasis studies, we are not provided the time dependent and specific cause for mortality. In comparing the groups did you attempt to identify death due to coagulopathy in the critical less-than-two-, two-tosix-, or six-to-twelve-hour windows?
Fourth, the TEG cohort could be disadvantaged by representing outdated managing principles. On the other hand, it is interesting to note that restricted crystalloid use did not appear to translate into a survival advantage.
Finally, I would submit that reduced use of FFP alone should be a considered improved outcome from the perspective of health care resource utilization.
In sum, I congratulate the Ben Taub group for this very timely report that should stimulate the evolution to goal-directed resuscitation. Thank you very much.
Dr. Mitchell Jay Cohen (San Francisco, California): There is a lot of discussion about coagulopathy in your presentation, but little data to suggest whether coagulopathy was fixed, whether coagulopathy contributed to death in either of the two groups.
I'm wondering what effect do you think either TEG associated resuscitation or 1:1 or any resuscitation milieu has on fixing coagulopathy. And do you think that's why these patients were dying or living better as a result of your therapy?
Dr. Andre Cap (Houston, Texas): I would just note that we found similar results in a study that we are presenting in the poster session tonight on what happened in theater with the implementation of ROTEM, which is a similar technology, as we all know.
Interestingly, the providers there who thought they were adhering to a 1:1:1 ratio ended up not doing that pre-ROTEM. When they used ROTEM, they got closer to 1:1:1 and they definitely used greater amounts of FFP, platelets, and, most strikingly, cryoprecipitate.
It would be interesting to know what happened with cryoprecipitate use in your study. Thanks very much.
Dr. John B. Holcomb (Houston, Texas): Dr. Tapia, TEG is an interesting device. You've shown decreased mortality by using TEG, yet you showed us not a single piece of data about TEG. No TEG algorithm, numbers of TEGs performed, TEG results.
It seems like you used the regular TEG, not rapid TEG, which means the TEG results came in 45 minutes or even later.
Please tell us more about the TEG algorithm that decreased mortality. Thank you very much.
Dr. Nicole Tapia (Houston, Texas): Drs. Moore, Cohen, Cap, and Holcomb, thank you for your comments. Due to the nature of this retrospective study, we cannot determine the sensitivity or specificity of our clinical judgment with respect to MTP activation because our trauma database and our blood bank did not capture MTP activations as part of their dataset. Moving forward we are collecting this data. However, for our current study, we activated MTP based on clinical judgment that the patient would require greater than 4 units RBCs for immediate management of shock.
With respect to TEG versus rTEG, interestingly, our hospital was the site for the development of Rapid Teg (rTEG) in 2008. We adjusted the amount of TF reagent to optimize the rate of the reaction and validated the rTEG data with the TEG that we already used with our trauma patients in cooperation with the manufacturer. In terms of the present era, the reason we don't currently use the rTEG is more of a technical/ skill issue on the part of the stat laboratory. While it is true that the reagents are multiple and more expensive (although not so much that they are cost prohibitive), the rTEG test is also more demanding of the technicians and requires special training and standardization runs for quality assurance. The standard TEG has worked well for our institution, has a true R-time for initiation of coagulation rather than the rTEG ACT used as a surrogate marker, and the initial results which tell us whether to replace FFP, platelets, or cryoprecipitate are available within 15 minutes. The threshold values for replacing products will be included in the final manuscript.
Because of the effectiveness of rapid transfusion devices, we can concurrently give RBC and FFP, with transfusion complete in a matter of minutes, thus prioritization is not an issue when we transfuse these patients. Cryoprecipitate was not included in our analysis because it was added to our MTP after the study dates we used in our evaluation. Prior to its addition to MTP, cryoprecipitate was rarely used, thus we did not include it in our study results and utilization was not significantly different in preMTP and MTP groups. Antifibrinolytics were not used in either group, but are now part of our protocol and we anticipate analysis of this in the future.
In comparing early death between the groups, we did not initially look at critical windows of time as suggested by Dr. Holcomb, but will certainly do so for the manuscript. We found no difference in nonsurvivable and survivable injury between the two groups.
Crystalloid is unfortunately a necessary evil during trauma resuscitation because NS is given with blood products during transfusion, whereas LR would be given if we were actively ''bolusing'' a patient. However, based on other literature we have reviewed, 7 liters of crystalloid (which was our average preMTP) is actually quite low, as compared to other institutions. Decreasing to an average of 4 liters likely reflects the patient receiving fewer boluses while waiting for blood products. We believe that the reason the decrease in crystalloid did not translate into a survival advantage is because we were already practicing restricted crystalloid use prior to MTP implementation.
Finally, we agree that reduced use of FFP alone is an improved outcome from the perspective of health care resource utilization, particularly since our institution is supported by the Harris County taxpayers.
Thank you all again for your questions.
